目的 调查分析恶性肿瘤患者的体成分结果，探讨不同营养状况、全身炎性反应之间体成分差异。 方法 收集2017年10月至2018年12月河北医科大学第一医院肿瘤科住院的恶性肿瘤患者，对纳入患者在入院24h之内进行一般资料调查、人体成分分析、营养状况评估、全身炎性反应评估以及实验室相关指标检测。比较不同性别、年龄、营养状况、全身炎性反应之间体成分的差异。 结果 纳入患者321例，男性186例，女性135例。在不同年龄、性别间，不同体质指数（BMI）、患者主观整体评估法（PG-SGA）间的细胞内外水分、蛋白质、体脂肪量、骨骼肌质量、上臂肌肉围度差异有统计学意义。同性别不同年龄组之间仅细胞外水分比率差异有统计学意义；改良格拉斯哥预后评分（mGPS）三组之间的细胞外水分比率、体脂肪量、内脏脂肪面积、上臂围度差异有统计学意义，且随炎症程度的增加而呈下降趋势。 结论 不同性别、PG-SGA、BMI、mGPS分组对恶性肿瘤患者体成分影响较大，且随着患者营养状况变差、炎症程度加重，体成分相关营养指标恶化加重。尽早纠正患者存在的营养不良和炎症状况，可明显改善患者体成分组成，为有效的个体化临床治疗提供支持。
Abstract
Objective Investigate and analyze the body composition results of patients with malignant tumors, and explore the differences in body composition between different nutritional statuses and systemic inflammatory responses to provide a basis for improving the accuracy of individualized clinical treatment. Methods To collect patients with malignant tumors who were hospitalized in the Department of Oncology of the First Hospital of Hebei Medical University from October 2017 to December 2018, and conduct general data survey, body composition analysis, nutritional status assessment, and systemic inflammatory response within 24hours of admission Evaluation and laboratory related index testing. Compare the differences in body composition between different genders, ages, nutritional status, and systemic inflammation. Results 321 patients were included, including 186males and 135 females. The statistical differences in body composition parameters between men and women of different age groups, different BMI, and PG-SGA are mainly reflected in intracellular and extracellular water, protein, body fat mass, skeletal muscle mass, upper arm muscle circumference, etc. Only the extracellular water ratio was statistically different between the same sex and different age groups；the extracellular water ratio, body fat mass, visceral fat area, upper arm circumference, etc. between the three groups of mGPS were statistically different, and the Increase and show a downward trend. Conclusion Different genders, PG-SGA, BMI, and mGPS groupings have a greater impact on body composition of patients with malignant tumors, and as the nutritional status of patients deteriorates and the degree of inflammation increases, the deterioration of nutritional indicators related to body composition worsens. Correcting the malnutrition and inflammation of the patient as soon as possible can significantly improve the patients body composition and provide support for effective individualized clinical treatment.
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1.PRADO C M M, LIEFFERS J R, MCCARGAR L J, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study［J］. Lancet Oncol, 2008, 9(7):605-607.
2.PRADO C M M, BARACOS V E, MCCARGAR L J, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity［J］. Clin Cancer Res, 2007, 13(11):3264-3268.
3.LIEFFERS J R, BATHE O F, FASSABENDER K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery［J］. Br J Cancer, 2012, 107(6):931-936.
4.CECCHINI S, CAVAZZINI E, MARCHESI F, et al. Computed tomography volumetric fat parameters versus body mass index for predicting short-term outcomes of colon surgery［J］. World J Surg, 2011, 35(2):415-423.
5.BLUETHMANN S M, MARIOTTO A B, ROWLAND J H. Anticipating the “Silver Tsunami”: Prevalence trajectories and comorbidity burden among older cancer survivors in the United States［J］. Cancer Epidemiol Biomarkers Prev, 2016, 25(7):1029-1036.
6.DEMARK-WAHNEFRIED W, PETERSON B L, WINER E P, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy［J］. J Clin Oncol, 2001, 19(9):2381-2389.
7.LIM S L, ONG K C, CHAN Y H, et al. Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality［J］. Clin Nutr, 2012, 31(3):345-350.
8.MURPHY K T, LYNCH G S. Editorial update on emerging drugs for cancer cachexia［J］. Expert Opin Emerg Drugs, 2012, 17(1):5-9.
9.KUMAR N B, KAZI A, SMITH T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment［J］. Curr Treat Options Oncol, 2010,11(3-4):107-117.
10.GRUNDMANN O, YOON S L, WILLIAMS J J. The value of bioelectrical impedance analysis and phase angle in the evaluation of malnutrition and quality of life in cancer patients—a comprehensive review［J］. Eur J Clin Nutr, 2015, 69(12):1290-1297.
11.崔久嵬, 刘雪莲, 李薇. 人体成分分析在抗肿瘤药物药动学及毒性预测中的研究进展［J］. 肿瘤代谢与营养电子杂志, 2018, 5(1):19-25.
12.YAMADA S, FUJII T, YABUSAKI N, et al. Clinical implication of inflammation-based prognostic score in pancreatic cancer［J］. Medicine, 2016, 95(18):e3582.
13.WEN-CHI CHOU, CHEN-YI KAO, PO-NAN WANG,et al.The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care［J］. BMC Palliat Care, 2015, 14(1):18.
14.李金海,朱明辉,蔡宇,等. 改良型格拉斯哥预后评分对肝门部胆管癌患者手术治疗预后评估的价值研究［J］. 浙江医学, 2018, 40(5):468-470.
15.宋旭敏, 任青, 程忠平. 格拉斯哥预后评分预测肿瘤的临床价值［J］. 医学综述, 2017(12):2354-2358.
16.HOPKINS J J, SAWYER M B. A review of body composition and pharmacokinetics in oncology［J］. Expert Rev Clin Pharmacol, 2017, 10(9):947-956.
17.SHACHAR S S, WILLIAMS G R, MUSS H B, et al. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review［J］. Eur J Cancer (Oxford, England:1990), 2016, 57:58-67.
18.SIMONSEN C, DE HEER P, BJERRE E D, et al. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology［J］. Ann Surg, 2018, 268(1):58-69.
19.STRULOV S S, DEAL A M, WEINBERG M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane based chemotherapy［J］. Clin Cancer Res, 2017, 23(3):658-665.
20.RICHARDS C H, ROXBURGH C S D, MACMILLAN M T, et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer［J］. PLoS One, 2012, 7(8):e41883.
21.KIM E Y, KIM Y S, SEO J Y, et al. The relationship between sarcopenia and systemic inflammatory response for cancer cachexia in small cell lung cancer［J］. PLoS One, 2016, 11(8):e0161125.
22.LAIRD B J, FALLON M, HJERMSTAD M J, et al. Quality of life in patients with advanced cancer: Differential association with performance status and systemic inflammatory response［J］. J Clin Oncol, 2016, 34(23):2769-2775.
23.MCSORLEY S T, BLACK D H, HORGAN P G, et al. The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer［J］.Clin Nutr, 2018, 37(4):1279-1285.
24.TANG P L, WANG H H, LIN H S, et al. Body composition early identifies cancer patients with radiotherapy at risk for malnutrition［J］. J Pain Symptom Manage, 2018, 55(3):864-871.
25.RYAN A M, POWER D G, DALY L, et al. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later［J］.Proc Nutr Soc, 2016, 75(2):199-211.
26.CAROLINA P, VELHO SONIA, LISA A, et al. Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer［J］.J Gastric Cancer, 2017, 17(1):74-87.
27.MARTIN L, BIRDSELL L, MACDONALD N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index［J］. J Clin Oncol, 2013, 31(12):1539-1547.
28.SARHILL N. Assessment of nutritional status and fluid deficits in advanced cancer［J］. Am J Hosp Palliat Care, 2003, 20(6):465-473.
基金
河北省重点研发计划项目健康医疗与生物医药专项（182777127D）
PDF(405 KB)
